Reports

Sale

Epidermal Growth Factor Receptor (EGFR) Inhibitors Market

Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market: By Indication: Lung Cancer, Colorectal Cancer, Breast Cancer, Others; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis, Key Indicators for Demand, Key Indicators for Price; Competitive Landscape; 2024-2032

Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Outlook

The global epidermal growth factor receptor (EGFR) inhibitors market is projected to grow at a CAGR of 8.6% during the forecast period of 2024-2032.

 

Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The growing incidences of cancer globally, along with the increasing geriatric population and lifestyle changes are some of the major drivers for the industry growth. Epidermal growth factor inhibitors (EGFRI) is the first targeted cancer therapy, which has become an essential treatment for many advance-stage epithelial cancers. In comparison to conventional chemotherapies, these agents have the superior ability to target cancer cells, further offering better safety profile to the patients.

 

Market Segmentation

Epidermal growth factor receptor (EGFR) inhibitors are medicines that slow down or stop EGFR’s activity, a protein found on the surface of some normal cells, by binding to its certain part. EGFR or epidermal growth factor receptor causes cells to divide upon binding to it by signalling pathways that control cell division and survival, leading to the growth of normal cells. Certain mutations in EGFR are known to be vulnerable and can lead to the growth of cancer cells.

The global epidermal growth factor receptor (EGFR) inhibitors industry can be divided based on segments like indication and region.

 

Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on indication, the industry can be segmented into:

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Others

The EMR report looks into the regional epidermal growth factor receptor (EGFR) markets like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.

 

Market Analysis

The global epidermal growth factor receptor inhibitors industry is being supported by the increase in the number of cancer cases such as lung cancer, colorectal cancer, breast cancer, and others. The growing incidences of cancer throughout the world also calls for more efficient therapy techniques that encourage scientists to create EGFR antibodies. Because of the busy lifestyle, excessive alcohol consumption and smoking habits, the incidence of cancer is quickly growing, particularly in regions like North America and Europe. The increasing morbidity and mortality rates among patients with cancer are leading to enhanced demand for EGFR antibodies, thus driving the market forward. Due to an enormous unmet need for new therapies to treat cancer symptoms, several pharmaceutical companies are focusing on the development of advanced EGFR inhibitors to capitalise on this enormous unmet need, which is expected to aid the industry over the forecast period.

 

Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global epidermal growth factor receptor (EGFR) inhibitors market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Amgen Inc. (NASDAQ: AMGN)
  • AstraZeneca 
  • Eli Lilly and Company 
  • F. Hoffmann-La Roche Ltd. 
  • Novartis AG
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Indication
  • Region
Breakup by Indication
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Amgen Inc.
  • Novartis AG
  • AstraZeneca PLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market (2018-2023) 
    8.3    Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast (2024-2032)
    8.4    Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market by Indication
        8.4.1    Lung Cancer
            8.4.1.1    Historical Trend (2018-2023)
            8.4.1.2    Forecast Trend (2024-2032)
        8.4.2    Colorectal Cancer
            8.4.2.1    Historical Trend (2018-2023)
            8.4.2.2    Forecast Trend (2024-2032)
        8.4.3    Breast Cancer
            8.4.3.1    Historical Trend (2018-2023)
            8.4.3.2    Forecast Trend (2024-2032)
        8.4.4    Others   
    8.5    Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market by Region
        8.5.1    North America
            8.5.1.1    Historical Trend (2018-2023) 
            8.5.1.2    Forecast Trend (2024-2032)
        8.5.2    Europe
            8.5.2.1    Historical Trend (2018-2023) 
            8.5.2.2    Forecast Trend (2024-2032)
        8.5.3    Asia Pacific
            8.5.3.1    Historical Trend (2018-2023) 
            8.5.3.2    Forecast Trend (2024-2032)
        8.5.4    Latin America
            8.5.4.1    Historical Trend (2018-2023) 
            8.5.4.2    Forecast Trend (2024-2032)
        8.5.5    Middle East and Africa
            8.5.5.1    Historical Trend (2018-2023) 
            8.5.5.2    Forecast Trend (2024-2032)
9    North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis
    9.1    United States of America 
        9.1.1    Historical Trend (2018-2023) 
        9.1.2    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Historical Trend (2018-2023) 
        9.2.2    Forecast Trend (2024-2032)
10    Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis
    10.1    United Kingdom
        10.1.1    Historical Trend (2018-2023) 
        10.1.2    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Historical Trend (2018-2023) 
        10.2.2    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Historical Trend (2018-2023) 
        10.3.2    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Historical Trend (2018-2023) 
        10.4.2    Forecast Trend (2024-2032)
    10.5   Others
11    Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis
    11.1    China
        11.1.1    Historical Trend (2018-2023) 
        11.1.2    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Historical Trend (2018-2023) 
        11.2.2    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Historical Trend (2018-2023) 
        11.3.2    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Historical Trend (2018-2023) 
        11.4.2    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.1    Historical Trend (2018-2023) 
        11.5.2    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis
    12.1    Brazil
        12.1.1    Historical Trend (2018-2023) 
        12.1.2    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Historical Trend (2018-2023) 
        12.2.2    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Historical Trend (2018-2023) 
        12.3.2    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East and Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis
    13.1    Saudi Arabia
        13.1.1    Historical Trend (2018-2023) 
        13.1.2    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Historical Trend (2018-2023) 
        13.2.2    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Historical Trend (2018-2023) 
        13.3.2    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Historical Trend (2018-2023) 
        13.4.2    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Competitive Landscape
    15.1    Market Structure
    15.2    Company Profiles
        15.2.1    Amgen Inc.
            15.2.1.1    Company Overview
            15.2.1.2    Product Portfolio
            15.2.1.3    Demographic Reach and Achievements
            15.2.1.4    Certifications
        15.2.2    Novartis AG
            15.2.2.1    Company Overview
            15.2.2.2    Product Portfolio
            15.2.2.3    Demographic Reach and Achievements
            15.2.2.4    Certifications
        15.2.3    AstraZeneca PLC
            15.2.3.1    Company Overview
            15.2.3.2    Product Portfolio
            15.2.3.3    Demographic Reach and Achievements
            15.2.3.4    Certifications
        15.2.4    Eli Lilly and Company
            15.2.4.1    Company Overview
            15.2.4.2    Product Portfolio
            15.2.4.3    Demographic Reach and Achievements
            15.2.4.4    Certifications
        15.2.5    F. Hoffmann-La Roche Ltd.
            15.2.5.1    Company Overview
            15.2.5.2    Product Portfolio
            15.2.5.3    Demographic Reach and Achievements
            15.2.5.4    Certifications
        15.2.6    Johnson & Johnson Services, Inc.
            15.2.6.1    Company Overview
            15.2.6.2    Product Portfolio
            15.2.6.3    Demographic Reach and Achievements
            15.2.6.4    Certifications
        15.2.7    Others
16    Key Trends and Developments in the Market


List of Key Figures and Tables

1.    Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market: Key Industry Highlights, 2018 and 2032
2.    Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market: Breakup by Indication (USD Million), 2018-2023
3.    Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast: Breakup by Indication (USD Million), 2024-2032
4.    Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market: Breakup by Region (USD Million), 2018-2023
5.    Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast: Breakup by Region (USD Million), 2024-2032
6.    North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
7.    North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
8.    Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
9.    Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
10.    Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
11.    Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
12.    Latin America Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
13.    Latin America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
14.    Middle East and Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
15.    Middle East and Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
16.    Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Structure

Key Questions Answered in the Report

The global epidermal growth factor receptor (EGFR) inhibitors market is projected to grow at a CAGR of nearly 8.6% in the forecast period of 2024-2032.

The major drivers of the industry include rising disposable incomes, increasing population, rising cases of cancer, increasing geriatric population, and the rising lifestyle changes.

The increasing cancer-related morbidity and mortality rates are expected to be the key trends guiding the growth of the industry.

North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market.

The leading indication segments in the industry include lung, colorectal, and breast cancer, among others.

The leading players in the market are Amgen Inc., AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Novartis AG, among others.

Analyst Review

The global epidermal growth factor receptor (EGFR) inhibitors market was driven by the rising cases of cancer. Aided by the changing lifestyles, the industry is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 8.6%.

EMR’s meticulous research methodology delves deep into the industry, covering the macro and micro aspects of the industry. Based on indication, the market can be segmented into lung, colorectal, and breast cancer, among others. The major regional markets for epidermal growth factor receptor (EGFR) inhibitors are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above industry include Amgen Inc., AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Novartis AG, among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER